



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/63102

Application Number
10/785,244

Filing Date
February 23, 2004

Examiner
Not Yet Assigned

Art Unit
1614

Invention Title
**Synthesis of Quetiapine and Pharmaceutically
Acceptable Salts Thereof**

Inventors
DILLER, et al.

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited
with the United States Postal Service with sufficient postage
as first class mail in an envelope addressed to: Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 9/8/04

Signature: Agrean

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.


3. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.
4. It is believed that no fees are due in connection with this Supplemental Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes

Dated: Sept 3, 2004

By: John B. Starr, Jr.
John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/63102	U.S. SERIAL NO. 10/785,244
	APPLICANT(S) Dov DILLER, et al.	
	FILING DATE February 23, 2004	GROUP 1614



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 240 228 A	October 7, 1987	EP				
	EP 0 282 236 A	September 14, 1988	EP				
	WO 01/55125 A	August 2, 2001	PCT				
	WO 99/06381 A	February 11, 1999	PCT				
	WO 03/080065 A	October 2, 2003	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Warawa E. J. et al., "Behavioral approach to nondyskinetic dopamine antagonists: Identification of Seroquel" <i>J. Med. Chem.</i> 2001 , 44,372-389

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	